Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer... Show more
KURA is expected to report earnings to rise 182.68% to -62 cents per share on May 01
Q1'25
Est.
$-0.62
Q4'24
Beat
by $0.35
Q3'24
Est.
$-0.63
Q2'24
Beat
by $0.04
Q1'24
Missed
by $0.04
The last earnings report on February 26 showed earnings per share of -21 cents, beating the estimate of -56 cents. With 1.25M shares outstanding, the current market capitalization sits at 515.22M.